1 biotics containing hydrolyzed cefotaxime and faropenem.

2            Disc susceptibility testing using faropenem (10 mug) is a simple, convenient, and highly p

3  ability of a disc susceptibility test using faropenem (10 mug) to predict carbapenemase activity in

4 ng the CLSI/EUCAST methodology with discs of faropenem (10 mug), temocillin (30 mug), and four carbap

5 nd 43.9% for temocillin, 57.1% and 98.8% for faropenem, 53.6% and 100% for the OXA-48 disk test, 98.8

6 s, a new algorithm incorporating temocillin, faropenem, and ICT which allows cost-effective detection

7 99% showed growth up to the edge of a 10-mug faropenem disc compared with only 6% of other beta-lacta

8  reference laboratory, growth up to a 10-mug faropenem disc correctly identified 84 of 86 carbapenema

9      A further prospective evaluation of the faropenem disc susceptibility test was performed using 2

10                A "double zone" around 10-mug faropenem discs was frequently associated with OXA-48 pr

11 Four phenotypic tests (temocillin disk test, faropenem disk test, OXA-48 disk test, and high-inoculum

12                      After choosing the best faropenem exposure, we performed experiments in which we

13 en and doses of linezolid, moxifloxacin, and faropenem identified are proposed to be adequate for all

14                    We have developed an oral faropenem-linezolid-moxifloxacin (FLAME) regimen that is

15                                          The faropenem medoxomil optimal dosage was 30 mg/kg 3-4 time

16 were AUC0-24/MIC ratios of 62 and 122, and a faropenem percentage of time above MIC >60%, in combinat

17 First, we varied the percentage of time that faropenem persisted above minimum inhibitory concentrati

18 e oral doses of linezolid, moxifloxacin, and faropenem that would achieve optimal target exposures as

19  of standard linezolid and moxifloxacin plus faropenem TMIC > 60%, as well as higher-dose moxifloxaci

20                                            A faropenem TMIC > 62% was associated with steepest microb

21 ine the effect of adding a third oral agent, faropenem, to this dual combination.